Long-Term Mortality Associated With Use of Carvedilol Versus Metoprolol in Heart Failure Patients With and Without Type 2 Diabetes: A Danish Nationwid...
Background Carvedilol may have favorable glycemic properties compared with metoprolol, but it is unknown if carvedilol has mortality benefit over metoprolol in patients with type 2 diabetes (T2D) and heart failure with reduced ejection fraction (HFrEF). Methods and Results Using Danish nationwide databases between 2010 and 2018, we followed patients with new-onset HFrEF treated with either carvedilol or metoprolol for all-cause mortality until the end of 2018. Follow-up started 120 days after initial HFrEF diagnosis to allow initiation of guideline-directed medical therapy. There were 39 260 p...
Elevated Stress Hormones Linked to Higher Risk of Hypertension, Cardiovascular Events
Adults with normal blood pressure and high levels of stress hormones were more likely to develop hyp...
Safety and efficacy of BNT162b2 mRNA COVID-19 vaccine through 6 months
Through 6 months of follow-up and despite a gradual decline in vaccine efficacy, the BNT162b2 (Pfize...
